Al-Ali HK - Search Results

1

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.

Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, Hähling D, Hegenbart U, Peter N, Schulze A, Florschütz A, Schmidt V, Reifenrath K, Zojer N, Junghanss C, Sayer HG, Maschmeyer G, Späth C, Hochhaus A, Fischer T, Al-Ali HK, Niederwieser D. Heinicke T, et al. Ann Hematol. 2021 Sep;100(9):2387-2398. doi: 10.1007/s00277-021-04565-1. Epub 2021 Jul 7. Ann Hematol. 2021. PMID: 34232360 Free PMC article. Clinical Trial.

2

High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.

Lange T, Günther C, Köhler T, Krahl R, Musiol S, Leiblein S, Al-Ali HK, van Hoomissen I, Niederwieser D, Deininger MW. Lange T, et al. Blood. 2003 Mar 15;101(6):2152-5. doi: 10.1182/blood-2002-05-1366. Epub 2002 Oct 24. Blood. 2003. PMID: 12406906 Free article. Clinical Trial.

3

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.

Bumm T, Müller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MW. Bumm T, et al. Blood. 2003 Mar 1;101(5):1941-9. doi: 10.1182/blood-2002-07-2053. Epub 2002 Oct 31. Blood. 2003. PMID: 12411298 Free article.

4

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Müller C, Niederwieser D, Druker BJ, Deininger MW. Al-Ali HK, et al. Hematol J. 2004;5(1):55-60. doi: 10.1038/sj.thj.6200319. Hematol J. 2004. PMID: 14745431

5

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW. Lange T, et al. Haematologica. 2004 Jan;89(1):49-57. Haematologica. 2004. PMID: 14754606

6

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.

Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG. Sorror ML, et al. J Clin Oncol. 2005 Jun 1;23(16):3819-29. doi: 10.1200/JCO.2005.04.569. Epub 2005 Apr 4. J Clin Oncol. 2005. PMID: 15809448

7

Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias.

Niederwieser D, Gentilini C, Hegenbart U, Lange T, Becker C, Wang SY, Bartsch K, Pönisch W, Raida M, Al-Ali H. Niederwieser D, et al. Crit Rev Oncol Hematol. 2005 Nov;56(2):275-81. doi: 10.1016/j.critrevonc.2005.03.016. Epub 2005 Oct 5. Crit Rev Oncol Hematol. 2005. PMID: 16213741 Review.

8

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.

Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Al-Ali H, Storer B, Maloney D, McSweeney P, Chauncey T, Agura E, Bruno B, Maziarz RT, Petersen F, Storb R. Hegenbart U, et al. J Clin Oncol. 2006 Jan 20;24(3):444-53. doi: 10.1200/JCO.2005.03.1765. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344316

9

Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML.

Niederwieser D, Lange T, Cross M, Basara N, Al-Ali H. Niederwieser D, et al. Best Pract Res Clin Haematol. 2006;19(4):825-38. doi: 10.1016/j.beha.2006.06.007. Best Pract Res Clin Haematol. 2006. PMID: 16997186 Review.

10

Rapid progression of Myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN-beta and copolymer-1 in a patient with multiple sclerosis.

Then Bergh F, Niklas A, Strauss A, von Ahsen N, Niederwieser D, Schwarz J, Wagner A, Al-Ali HK. Then Bergh F, et al. Acta Haematol. 2006;116(3):207-10. doi: 10.1159/000094683. Acta Haematol. 2006. PMID: 17016041

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters